Biotech Specialty Pharma

Biovest International

324 S. Hyde Park Ave., Suite 350
Tampa, FL 33606 USA
Phone
Fax
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Manufacturer of biological drugs to treat cancer.

Management Francis E. O'Donnell, Jr. MD Chairman; Samuel S. Duffey, Esq. President and General Counsel; Mark Hirschel, Ph.D. Chief Scientific Officer; Alan Pearce, Chief Financial Officer; David D. Moser, Corporate Secretary;

Click here for Financial Data
Keywords: Oncology, immunotherapy, Non-Hodgkin lymphoma

Comment


Updated: Nov. 29, 2016


Description

Biovest International is a majority-owned subsidiary of Accentia Biopharmaceuticals Inc., a vertically integrated specialty biopharmaceutical company with services to commercialize targeted therapeut......view more

Products / Services

Biovest is currently conducting clinical trials on BiovaxID(tm), a cancer immunotherapy vaccine for Non-Hodgkin's Lymphoma.......view more

Market / Customers

There are approximately 65,000 new cases of non-Hodgkin's lymphoma diagnosed each year in the US with a comparable number in Europe.......view more


Strategy

A core mission of Biovest is to its our expertise in hollow fiber to advance personalized medicine and make it a reality. In addition to manufacturing Biovest's proprietary vaccine, the company is wo...view more

Revenue / Funding

For over 10 years the company has operated the National Cell Culture Center (NCCC) under a grant from the National Institutes of Health....view more

RELATED COMPANIES



0000-00-00-4520